Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
| Autor: | Liu, Jian Ping, Zhang, Ying, Xia, Ru-yu, Liang, Shi-bing, Hu, Xiao-yang, Dai, Meng-yuan, Li, Yi-lin, Zhao, Le-yi, Moore, Michael, Fei, Yu-tong, Liu, Jian-ping, Hu, Xiaoyang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
0211 other engineering and technologies 02 engineering and technology Respiratory tract infections Placebo Acute Pharyngitis Herpangina law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine 021105 building & construction medicine Sore throat Adverse effect Miscellaneous systems and treatments business.industry RZ409.7-999 Common cold Shufeng Jiedu medicine.disease 030205 complementary & alternative medicine Complementary and alternative medicine Randomized controlled trials Systematic review Original Article Chinese herbal medicine medicine.symptom business |
| Zdroj: | Integrative Medicine Research, Vol 10, Iss 3, Pp 100726-(2021) Integrative Medicine Research |
| ISSN: | 2213-4220 |
| Popis: | Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs.Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms.Results: Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD −1.54 days, 95% CI [−2.15,−0.92], I2 = 80%, n = 385, 3 trials) and cough (MD −1.22 days, 95% CI [−1.52, −0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [−1.15, −0.21], I2 = 68%, n = 140, 2 trials) and blistering (MD −0.99 days, 95% CI [−1.23, −0.76], n = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD −1.13 days, 95% CI [−1.36, −0.90], I2 = 33%, n = 688, 7 trials) and sore throat (MD −1.13 days, 95% CI [−1.40, −0.86], I2 = 84.1%, n = 1194, 10 trials). SFJD also improving their cure rate with a range (1–5 days). No serious adverse events were reported.Conclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|